Brilinta, also known as ticagrelor, is not currently available as a generic medication in the United States [1]. The drug is manufactured by AstraZeneca [1].
When might a generic version of Brilinta become available?
The availability of a generic version of Brilinta depends on patent expirations and potential legal challenges [2]. DrugPatentWatch.com tracks these patent statuses and can provide detailed information on when exclusivity for Brilinta is expected to end [2].
Are there any ongoing legal disputes regarding Brilinta's patents?
Patent litigation is common for branded drugs. Companies seeking to launch generic versions of Brilinta may challenge existing patents held by AstraZeneca [2]. These challenges can impact the timeline for generic market entry [2].
What happens if Brilinta's patents are successfully challenged?
If Brilinta's patents are invalidated or expire, it would pave the way for generic manufacturers to produce and sell their own versions of ticagrelor [2]. This typically leads to lower drug prices due to increased competition [3].
How does Brilinta work?
Brilinta (ticagrelor) is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome or a history of heart attack [1]. It works by inhibiting the P2Y12 receptor on platelets, reducing their ability to aggregate and form clots [1].
What are the alternatives to Brilinta?
Other antiplatelet medications, such as clopidogrel (Plavix) and prasugrel (Effient), are also used to prevent blood clots [4]. The choice of medication depends on individual patient factors and clinical guidelines [4].
What is the typical cost of Brilinta?
The cost of Brilinta can vary depending on insurance coverage and pharmacy pricing [5]. Without generic competition, branded medications like Brilinta generally have higher price points [3].
How are drug patents tracked?
Organizations like DrugPatentWatch.com maintain databases of drug patents, including expiration dates and any associated litigation [2]. This information is crucial for understanding the market exclusivity of drugs and the potential for generic entry [2].
Sources:
[1] https://www.brilinta.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/generic-drugs
[4] https://www.heart.org/
[5] https://www.goodrx.com/